Malignancy and rheumatoid arthritis

被引:32
|
作者
Askling J. [1 ]
机构
[1] Clinical Epidemiology Unit M9:01, Department of Medicine Solna, Karolinska University Hospital Solna
关键词
Rheumatoid Arthritis; Cancer Risk; Abatacept; Cancer Occurrence; Rheumatoid Arthritis Treatment;
D O I
10.1007/s11926-007-0067-1
中图分类号
学科分类号
摘要
The occurrence of cancer is not an infrequent event in patients with rheumatoid arthritis (RA). Indeed, following diagnosis of RA at a typical age (55 years), one in five patients will be diagnosed with cancer. In the vast majority of such cases, the cancer has nothing to do with RA or its treatment; rather, it represents the "background" risk applicable to all humans. In some cases, the cancer occurs as a result of factors also associated with the risk of developing RA (eg, smoking), even though no direct link exists between the cancer and the RA. In a fraction of cases, however, the cancer is causally associated with the RA disease or its treatments. This review summarizes our current understanding of the occurrence of cancer in RA, possible links to RA disease and to traditional and newer RA treatments. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:421 / 426
页数:5
相关论文
共 50 条
  • [21] Incidence of Malignancy and the Risk of Lymphoma in Japanese Patients with Rheumatoid Arthritis Compared to the General Population
    Hashimoto, Atsushi
    Chiba, Noriyuki
    Tsuno, Hirotaka
    Komiya, Akiko
    Furukawa, Hiroshi
    Matsui, Toshihiro
    Nishino, Jinju
    Tohma, Shigeto
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (04) : 564 - 571
  • [22] The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
    Cho, Soo-Kyung
    Lee, Jiyoung
    Han, Minkyung
    Bae, Sang-Cheol
    Sung, Yoon-Kyoung
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [23] The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
    Soo-Kyung Cho
    Jiyoung Lee
    Minkyung Han
    Sang-Cheol Bae
    Yoon-Kyoung Sung
    Arthritis Research & Therapy, 19
  • [24] Preclinical Rheumatoid Arthritis and Rheumatoid Arthritis Prevention
    Deane, Kevin D.
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (08)
  • [25] Epidemiology of rheumatoid arthritis: Rheumatoid arthritis and mortality
    Myasoedova E.
    Davis III J.M.
    Crowson C.S.
    Gabriel S.E.
    Current Rheumatology Reports, 2010, 12 (5) : 379 - 385
  • [26] Preclinical rheumatoid arthritis and rheumatoid arthritis prevention
    Greenblatt, H. Karl
    Kim, Hyoun-Ah
    Bettner, Leah F.
    Deane, Kevin D.
    CURRENT OPINION IN RHEUMATOLOGY, 2020, 32 (03) : 289 - 296
  • [27] Risk of serious infection, malignancy, or death in Japanese rheumatoid arthritis patients treated with a combination of abatacept and tacrolimus: a retrospective cohort study
    Tokunaga, Kenichiro
    Matsui, Kunihiko
    Oshikawa, Hideto
    Matsui, Toshihiro
    Tohma, Shigeto
    CLINICAL RHEUMATOLOGY, 2021, 40 (05) : 1811 - 1817
  • [28] Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study
    Kim, Seoyoung C.
    Pawar, Ajinkya
    Desai, Rishi J.
    Solomon, Daniel H.
    Gale, Sara
    Bao, Min
    Sarsour, Khaled
    Schneeweiss, Sebastian
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 49 (02) : 222 - 228
  • [29] The Burden of Disease in Rheumatoid Arthritis
    Till Uhlig
    Rikke H. Moe
    Tore K. Kvien
    PharmacoEconomics, 2014, 32 : 841 - 851
  • [30] Emerging drugs for rheumatoid arthritis
    Voulgari, Paraskevi V.
    EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (01) : 175 - 196